Advanced search
Publication Cover
Journal of Chemotherapy Volume 34, 2022 - Issue 7
Submit an article Journal homepage
311
Views
4
CrossRef citations to date
0
Altmetric
Anticancer Original Research Papers

FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer

Seval Aya School of Medicine, Department of Medical Oncology, Medeniyet University, Istanbul, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7555-2657
ORCID Icon,
Muhammed Mustafa Atcıb Department of Medical Oncology, Cemil Taşcıoğlu City HospitalORCID Iconhttps://orcid.org/0000-0002-1300-3695
ORCID Icon,
Rukiye Arıkanc School of Medicine, Department of Medical Oncology, Marmara UniversityORCID Iconhttps://orcid.org/0000-0003-2688-1515
ORCID Icon,
Özgecan Dülgara School of Medicine, Department of Medical Oncology, Medeniyet University, Istanbul, TurkeyORCID Iconhttps://orcid.org/0000-0002-0678-4024
ORCID Icon,
Deniz Tataroğlu Özyükselerd Department of Medical Oncology, Istanbul Kartal Lutfi Kirdar Education and Training HospitalORCID Iconhttps://orcid.org/0000-0002-0254-1084
ORCID Icon,
Nail Paksoye School of Medicine, Department of Medical Oncology, Istanbul UniversityORCID Iconhttps://orcid.org/0000-0003-4636-2595
ORCID Icon,
İzzet Doğane School of Medicine, Department of Medical Oncology, Istanbul UniversityORCID Iconhttps://orcid.org/0000-0003-1018-1119
ORCID Icon,
Buğra Öztosuna School of Medicine, Department of Medical Oncology, Medeniyet University, Istanbul, TurkeyORCID Iconhttps://orcid.org/0000-0003-2309-6781
ORCID Icon,
Didem Taştekinf School of Medicine, Department of Medical Oncology, Bahçeşehir UniversityORCID Iconhttps://orcid.org/0000-0002-9522-9849
ORCID Icon,
Başak Bala Övenf School of Medicine, Department of Medical Oncology, Bahçeşehir UniversityORCID Iconhttps://orcid.org/0000-0002-9921-4089
ORCID Icon &
Mahmut Gümüşa School of Medicine, Department of Medical Oncology, Medeniyet University, Istanbul, TurkeyORCID Iconhttps://orcid.org/0000-0003-3550-9993
ORCID Icon show all
Pages 465-471 | Received 16 Sep 2021, Accepted 03 Jan 2022, Published online: 17 Jan 2022

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30.
  • Midha S, Chawla S, Garg PK. Modifiable and non-modifiable risk factors for pancreatic cancer: a review. Cancer Lett. 2016;381(1):269–277.
  • Huang J, Lok V, Ngai CH, et al. Worldwide burden of, risk factors for, and trends in pancreatic cancer. Gastroenterology. 2021;160(3):744–754.
  • Stopa KB, Kusiak AA, Szopa MD, et al. Pancreatic cancer and its microenvironment-recent advances and current controversies. Int J Mol Sci. 2020;21(9).
  • AC Society. Cancer facts & figures 2020. Atlanta, GA: American Cancer Society; 2020.
  • Luchini C, Capelli P, Scarpa A. Pancreatic ductal adenocarcinoma and its variants. Surg Pathol Clin. 2016;9(4):547–560.
  • Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–2413.
  • O'Reilly EM, Surinach A, Wu Z, et al. Real-world patterns of care among patients with metastatic pancreatic cancer (mPC). Gastrointestinal Cancers Symposium 2020; San Francisco. JCO. 2020;38(4_suppl):666.
  • McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846–4861.
  • Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet. 2016;388(10039):73–85.
  • Qian Y, Gong Y, Fan Z, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2020;13(1):130.
  • Chandana S, Babiker HM, Mahadevan D. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC). Expert Opin Investig Drugs. 2019;28(2):161–177.
  • Singh RR, O'Reilly EM. New treatment strategies for metastatic pancreatic ductal adenocarcinoma. Drugs. 2020;80(7):647–669.
  • Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825.
  • Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703.
  • Chan KKW, Guo H, Cheng S, et al. Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: a population-based propensity score-weighted analysis. Cancer Med. 2020;9(1):160–169.
  • Lee JC, Woo SM, Shin DW, et al. Comparison of FOLFIRINOX and gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer: using Korean pancreatic cancer (K-PaC) registry. Am J Clin Oncol. 2020;43(9):654–659.
  • Kang J, Hwang I, Yoo C, et al. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Invest New Drugs. 2018;36(4):732–741.
  • Chllamma MK, Cook N, Dhani NC, et al. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. Br J Cancer. 2016;115(6):649–654.
  • Ramanathan RK, McDonough SL, Philip PA, et al. Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J Clin Oncol. 2019;37(13):1062–1069.
  • Cartwright TH, Parisi M, Espirito JL, et al. Clinical outcomes with first-line chemotherapy in a large retrospective study of patients with metastatic pancreatic cancer treated in a US community oncology setting. Drugs Real World Outcomes. 2018;5(3):149–159.
  • Wang Y, Camateros P, Cheung WY. A Real-World comparison of FOLFIRINOX, gemcitabine plus nab-Paclitaxel, and gemcitabine in advanced pancreatic cancers. J Gastrointest Cancer. 2019;50(1):62–68.
  • Hegewisch-Becker S, Aldaoud A, Wolf T, et al. Results from the prospective german TPK clinical cohort study: treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. Int J Cancer. 2019;144(5):981–990.
  • Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–2406.
  • Tempero MA, Reni M, Riess H, et al. APACT: phase III, multi- center, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. JCO. 2019;(37(15_suppl):4000–4000.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.